Date of purchase: 06/01/2025
Number of ordinary shares purchased: 398,013
Volume weighted average price paid per ordinary share (GBp): 53.4122 |
Over the past 12 months IP Group has cancelled 61,408,217 shares.
==================================================================
31 December 2024
IP Group plc - Voting Rights and Capital - Month End Disclosure
Pursuant to Disclosure and Transparency Rule 5.6.1:
As at the date of this announcement, the Company has 975,286,268 Shares in issue and is not holding any Shares in Treasury.
The total number of voting rights in IP Group plc is therefore 975,286,268. |
You'd hope so. As you have to get your largest investments right. I've no idea of the additional monthly running costs to IPO. |
Actually I take it back. Not enough homework on this, must be some logical explanation. |
This still waiting on Istesso is rubbish. They have board representation and still pretending they don't know what is going on. The trials are done and dusted, web site gathering 12 months dust. Time to move on and hold someone in IPO accountable rather than hoping for a miracle and paying a pile of hangers on for a single post promoting world arthritis day a few months ago. |
ONT joins the FTSE 350 on Monday. |
Date of purchase: 20/12/2024
Number of ordinary shares purchased: 500,000
Volume weighted average price paid per ordinary share (GBp): 52.4919 |
I still don't get how at the start of the year. Expectation was for istesso to deliver trial results end H1. So coming upto 6 months late. Not good when IPO are main shareholder. |
Honestly, for a company with many really exciting investments.
I nearly fell asleep before 6 minutes. Need a coffee first! |
9 minute recap, nothing new.
Still awaiting istesso
More buy backs....
9 minutes wasted. |
Edison vid interview.
Editing TV. |
hxxps://youtu.be/mI58ikT9occ?si=dS65KCh5xhWFK2zM
CEO giving an update.. released today! |
End June NAV was 104p I doubt this has changed much. A small uplift from disposals maybe, but definitely more confidence in the valuation of the remaining assets.
Still a huge discount. With the buy backs still to come at over 85m shares, risk is substantially reduced. Dyor. |
Makes you wonder, if two holdings give you a very decent uplift of 40%ish. Then makes you wonder about the valuation across its portfolio say 20% uplift and some of its holdings should be way above that. Still say share price is way under valued. Will keep adding when I have spare money. |
Fees? Some other costs? |
IUG sale income on my calcs £9.4m, IPGroup says £8.8m.
I am reasonably confident in my calcs based on the declared holding and the value of the deal, so why the discrepancy?
I'll double check later. |
 IP Group plc - Two quoted life sciences portfolio companies receive cash offers
- Anticipated further £13.8m of cash proceeds
- Intention to use c.20% of proceeds to further increase share buyback programme
IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, is pleased to note that two quoted companies in its life sciences portfolio have received cash offers.
Intelligent Ultrasound Group plc, in which the Group has a 20.8% holding, received a cash offer from Surgical Science Sweden AB which values the business at approximately £45.2m. As a result, IP Group expects to receive £8.8m of cash for its holding, which would represent an uplift of £4.4m (100%) from the last-reported NAV at 30 June 2024. This will replace the previously anticipated distribution, following the sale of the company's AI business. The Group will provide a further update following completion, which is subject to, among other things, shareholder approval.
In addition, Abliva AB, which discovers and develops medicines for the treatment of mitochondrial disease and in which the Group has a 9.5% stake, received a cash offer from Pharming Technologies BV which values that business at approximately SEK 725.3m (£52.4m*).
As a result, IP Group expects to receive £5m total cash for its holding, which would represent a multiple of 1.5 times cost and an uplift in carrying value of £3.7m (284%) since the last-reported NAV at 30 June 2024. Completion is conditional on customary conditions and the Group will provide a further update following completion.
Greg Smith, Chief Executive of IP Group, said: "We're pleased to see continued interest in our life sciences portfolio following the successful sale of Kynos Therapeutics in October. Our congratulations go to Stuart Gall and the Intelligent Ultrasound team and to Ellen Donnelly and the team at Abliva."
The Group anticipates using approximately 20% of the proceeds from these transactions, which are expected to complete in 2025, to further increase the Group's current share buyback programme, in line with its capital allocation policy.
*GBP equivalent using 13.8311 SEK/GBP |
Date of purchase: 19/12/2024
Number of ordinary shares purchased: 700,000
Volume weighted average price paid per ordinary share (GBp): 50.9940 |
IP Group plc - Two quoted life sciences portfolio companies receive cash offers
- Anticipated further £13.8m of cash proceeds
- Intention to use c.20% of proceeds to further increase share buyback programme |
63p+ by the time a tender offer arrives. |
There's a limit in terms of what is even possible given liquidity. I'd prefer a chunky tender offer at 55p. |
£40m of buybacks once the current £15m programme ends.
Better than nothing, but somewhat underwhelmning when "the Group anticipates gross cash and deposits of £279m after the receipt of the Featurespace funds which is expected before the year-end."
I don't know what the share register looks like, but that much unspent cash must surely be attractive to corporate predators like Saba... |
IUG news has now made it to the website.
A reasonable uplift in book value [prior share price was NAV]
Parkwalk do well out of this as they also hold IUG [approx 10%]
==================================================================
Intelligent Ultrasound Group plc - Recommended cash acquisition by Surgical Science Sweden AB 19 Dec 2024
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION
FOR IMMEDIATE RELEASE
19 DECEMBER 2024
RECOMMENDED CASH ACQUISITION
of Intelligent Ultrasound Group plc ("Intelligent Ultrasound")
by Surgical Science Sweden AB ("Surgical Science")
to be effected by means of a Scheme of Arrangement under Part 26 of the Companies Act 2006
Summary
· The boards of Surgical Science and Intelligent Ultrasound are pleased to announce that they have reached agreement on the terms of a recommended cash acquisition to be made by Surgical Science for the entire issued and to be issued ordinary share capital of Intelligent Ultrasound (the "Acquisition"). It is intended that the Acquisition be implemented by means of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act (the "Scheme" or "Scheme of Arrangement").
· Under the terms of the Acquisition, Intelligent Ultrasound Shareholders shall be entitled to receive:
13 pence in cash for each Intelligent Ultrasound Share held (the "Acquisition Price")
· The Acquisition Price values the entire issued and to be issued ordinary share capital of Intelligent Ultrasound at approximately £45.2 million on a fully diluted basis.
· The Acquisition Price represents a premium of approximately:
· 16.9% to the Closing Price per Intelligent Ultrasound Share of 11.13 pence on 18 December 2024 (being the last Business Day prior to the publication of this announcement);
· 31.1% to the volume-weighted average price per Intelligent Ultrasound Share of 9.91 pence for the 12-month period ended 18 December 2024 (being the last Business Day prior to the publication of this announcement); and
· 79.3% to the Closing Price per Intelligent Ultrasound Share of 7.25 pence on 17 July 2024 (being the last Business Day prior to the publication of the announcement of the sale of the Clinical AI Business).... |
palisz, Good stuff! I was away from the desk at the time, as making lunch!
Odd that IUG news has not been noted.
Not certain, but it looks like another has been sold, Abliva.
IPO have 9.5% [worth approx at t/o price $6,279,500]
=================================================
Do you think we should all pray for the shorter?
================================================= |
Thanks Bamboo. I put up highlights just to be sure people know something is out.
good to follow up with whole release. |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
